Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

BMY Q1 2026

Bristol Myers Squibb's first-quarter 2026 update centered on growth-portfolio execution across oncology, hematology, immunology and cardiovascular products while legacy-product erosion and pipeline delivery remained central to the outlook.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline.
  • Improved manufacturing and site expansion can increase patient throughput for Breyanzi and Abecma.
  • Clinical and regulatory milestones can refresh the portfolio across oncology, immunology and neuroscience.

Risks that still need monitoring

  • Loss of exclusivity

    Generic and biosimilar competition can accelerate declines in major legacy products.

  • Pipeline replacement risk

    Clinical setbacks or slow launches could leave growth products unable to replace lost legacy revenue.

  • Leverage and capital allocation

    Acquisition-related debt can constrain flexibility while integration and milestone payments consume cash.

Primary sources

Bristol Myers Squibb Reports First Quarter 2026 Financial ResultsBristol-Myers Squibb Company · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/23/2026, 12:00:00 AM

Open original source
Bristol-Myers Squibb Company Investor RelationsBristol-Myers Squibb Company · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Bristol Myers Squibb SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/23/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research